Piper Sandler raises target for Viatris stock to USD 14.00

Published on 10/29/2026 at 13:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viatris reported USD 3.76 billion in second-quarter revenue. Viatris stock stood at EUR 17.13 on October 29, 2026, with results due November 5, 2026.

Deal expands innovative medicines

Viatris agreed to acquire Pacira for USD 1.65 billion on October 8, 2026.
Pacira generated USD 746 million in revenue during the twelve months ended June 30, 2026.
Pacira reported USD 177 million in adjusted EBITDA for the same period.

Viatris, US92556V1061, Illustration mit AI erstellt.

Viatris Inc. (ISIN US92556V1061) received a higher price target from Piper Sandler on October 26, 2026, which lifted its view from USD 13.00 to USD 14.00, according to MarketScreener. The adjustment came as Viatris prepares to integrate a major specialty-pharmaceutical acquisition.

Pacira adds a specialty platform

Viatris agreed to acquire Pacira BioSciences on October 8, 2026, for USD 1.65 billion in equity value, according to the company's Viatris release. The transaction adds EXPAREL and ZILRETTA, two marketed non-opioid pain treatments, and is expected to close by the end of 2026.

Pacira generated USD 746 million in total revenue and USD 177 million in adjusted EBITDA during the twelve months ended June 30, 2026. Viatris said the transaction should be immediately accretive to its financial guidance metrics, while funding is expected to come mainly from excess cash.

What does Pacira add?

The acquisition gives Viatris an established commercial platform in non-opioid pain therapies rather than another early-stage research bet. Pacira's two products address postsurgical pain and osteoarthritis knee pain, while the deal also adds U.S. commercial, market-access, medical-affairs and research capabilities.

Three dated steps for Viatris

On October 5, 2026, Viatris announced a November 5, 2026 reporting date. On October 8, 2026, it announced the USD 1.65 billion Pacira transaction. On October 26, 2026, Piper Sandler raised its target from USD 13.00 to USD 14.00, as MarketScreener reported.

Upcoming reporting date

Viatris is scheduled to release third-quarter 2026 results on November 5, 2026, with management due to discuss the results and the Pacira transaction, according to its Viatris announcement.

Viatris stock after the target update

Viatris was trading intraday at EUR 17.13 at Lang & Schwarz on October 29, 2026 at 1:45 p.m. CEST. The available Xetra reference did not provide a dated close for October 28, 2026, so no daily percentage comparison is stated.

The further course of trading is shown by the continuously updated real-time quote of Viatris stock.